//
//
EIC funding call for RNA-based therapies and diagnostics for rare genetic diseases

EIC funding call for RNA-based therapies and diagnostics for rare genetic diseases

The EIC Transition 2022 (HORIZON-EIC-2022-TRANSITION-01) call, which has opened on March 1st, is intended to meet the following specific objectives:

  1. Advance, beyond the state-of-the-art, RNA delivery methods, including robust mRNA formulations, that would enable effective and safe delivery of mRNA into the cells;
  2. Design, develop and preclinical validate of novel miRNAs (miRNA lncRNA, tRNA or siRNA-based) therapies for complex or rare genetic diseases;
  3. Develop and validate novel RNA-based diagnostics and RNA-based predictive biomarkers that would allow for early and more accurate diagnosis and for favourable or non- post-treatment prognosis, respectively.

For more information please visit EJP RD website.

Recent News

Applications should be submitted at bonesecr@strutture.univaq.it and should include a detailed CV with a complete list of publications and other relevant achievements.Place of Work: University of L’Aquila, Italy, Department of...
We are seeking a highly motivated post-doctoral researcher interested in osteo-immunology to join our team and work on the diversity of osteoclasts, the multinucleated monocytic cells involved in bone resorption.We...
THREE ITC GRANTS are available for PhD students and Young Researchers and Innovators (YRI) that are WG members of GEMSTONE  from COST Inclusiveness Target Countries (ITC) and Near Neighbor Country (NNC)....
The EIC Transition 2022 (HORIZON-EIC-2022-TRANSITION-01) call, which has opened on March 1st, is intended to meet the following specific objectives: Advance, beyond the state-of-the-art, RNA delivery methods, including robust mRNA formulations, that would...
Please find in the following a simple step by step guide on how to nominate colleagues from the same country of affiliation to represent you in MC meetings in e-cost:
JOIN US AT THE EUROPEAN CALCIFIED TISSUE SOCIETY CONGRESS FOR: